

David A Six

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6708487/publications.pdf>

Version: 2024-02-01

39
papers

4,073
citations

257450

24
h-index

302126

39
g-index

42
all docs

42
docs citations

42
times ranked

5630
citing authors

#	ARTICLE	IF	CITATIONS
1	Fluorescent sensors of siderophores produced by bacterial pathogens. <i>Journal of Biological Chemistry</i> , 2022, 298, 101651.	3.4	12
2	Iron Acquisition Systems of Gram-negative Bacterial Pathogens Define TonB-Dependent Pathways to Novel Antibiotics. <i>Chemical Reviews</i> , 2021, 121, 5193-5239.	47.7	64
3	The Next-Generation $\hat{1}^2$ -Lactamase Inhibitor Taniborbactam Restores the Morphological Effects of Cefepime in KPC-Producing <i>Escherichia coli</i> . <i>Microbiology Spectrum</i> , 2021, 9, e0091821.	3.0	5
4	VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo- $\hat{1}^2$ -Lactamases, Restores Activity of Cefepime in <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	123
5	Metabolic phospholipid labeling of intact bacteria enables a fluorescence assay that detects compromised outer membranes. <i>Journal of Lipid Research</i> , 2020, 61, 870-883.	4.2	11
6	Defects in Efflux (<i>oprM</i>), $\hat{1}^2$ -Lactamase (<i>ampC</i>), and Lipopolysaccharide Transport () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Z61. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	7
7	Development and Optimization of a Higher-Throughput Bacterial Compound Accumulation Assay. <i>ACS Infectious Diseases</i> , 2019, 5, 394-405.	3.8	19
8	Advances and challenges in bacterial compound accumulation assays for drug discovery. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 9-15.	6.1	35
9	Molecular Probes for the Determination of Subcellular Compound Exposure Profiles in Gram-Negative Bacteria. <i>ACS Infectious Diseases</i> , 2018, 4, 1355-1367.	3.8	17
10	The sialic acid transporter NanT is necessary and sufficient for uptake of 3-deoxy-d-manno-oct-2-ulosonic acid (Kdo) and its azido analog in <i>Escherichia coli</i> . <i>Molecular Microbiology</i> , 2018, 110, 204-218.	2.5	19
11	A pathway-directed positive growth restoration assay to facilitate the discovery of lipid A and fatty acid biosynthesis inhibitors in <i>Acinetobacter baumannii</i> . <i>PLoS ONE</i> , 2018, 13, e0193851.	2.5	13
12	Subcellular Chemical Imaging of Antibiotics in Single Bacteria Using C_{60} -Secondary Ion Mass Spectrometry. <i>Analytical Chemistry</i> , 2017, 89, 5050-5057.	6.5	71
13	Molecular characterization and verification of azido-3,8-dideoxy-d-manno-oct-2-ulosonic acid incorporation into bacterial lipopolysaccharide. <i>Journal of Biological Chemistry</i> , 2017, 292, 19840-19848.	3.4	25
14	Characterization of an <i>Acinetobacter baumannii</i> <i>lptD</i> Deletion Strain: Permeability Defects and Response to Inhibition of Lipopolysaccharide and Fatty Acid Biosynthesis. <i>Journal of Bacteriology</i> , 2016, 198, 731-741.	2.2	57
15	Deletion of the $\hat{1}^2$ -Acetoacetyl Synthase FabY in <i>Pseudomonas aeruginosa</i> Induces Hypoacylation of Lipopolysaccharide and Increases Antimicrobial Susceptibility. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 153-161.	3.2	10
16	Complex transcriptional and post-transcriptional regulation of an enzyme for lipopolysaccharide modification. <i>Molecular Microbiology</i> , 2013, 89, 52-64.	2.5	45
17	Pathogenicity of <i>Yersinia pestis</i> Synthesis of 1-Dephosphorylated Lipid A. <i>Infection and Immunity</i> , 2013, 81, 1172-1185.	2.2	24
18	Phosphate Groups of Lipid A Are Essential for <i>Salmonella enterica</i> Serovar Typhimurium Virulence and Affect Innate and Adaptive Immunity. <i>Infection and Immunity</i> , 2012, 80, 3215-3224.	2.2	70

#	ARTICLE	IF	CITATIONS
19	Density gradient enrichment of <i>Escherichia coli</i> lpxL mutants. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2012, 1821, 989-993.	2.4	1
20	A live attenuated strain of <i>Yersinia pestis</i> KIM as a vaccine against plague. <i>Vaccine</i> , 2011, 29, 2986-2998.	3.8	41
21	Lipopolysaccharide (LPS) Inner-Core Phosphates Are Required for Complete LPS Synthesis and Transport to the Outer Membrane in <i>Pseudomonas aeruginosa</i> PAO1. <i>MBio</i> , 2011, 2, .	4.1	50
22	Palmitoylation State Impacts Induction of Innate and Acquired Immunity by the <i>Salmonella enterica</i> Serovar Typhimurium <i>msbB</i> Mutant. <i>Infection and Immunity</i> , 2011, 79, 5027-5038.	2.2	42
23	Correction: <i>Salmonella</i> Synthesizing 1-Monophosphorylated Lipopolysaccharide Exhibits Low Endotoxic Activity while Retaining Its Immunogenicity. <i>Journal of Immunology</i> , 2011, 187, 3449-3449.	0.8	6
24	<i>Salmonella</i> Synthesizing 1-Monophosphorylated Lipopolysaccharide Exhibits Low Endotoxic Activity while Retaining Its Immunogenicity. <i>Journal of Immunology</i> , 2011, 187, 412-423.	0.8	66
25	Lipidomics reveals a remarkable diversity of lipids in human plasma. <i>Journal of Lipid Research</i> , 2010, 51, 3299-3305.	4.2	1,071
26	Purification and Characterization of the Lipid A 1-Phosphatase LpxE of <i>Rhizobium leguminosarum</i> . <i>Journal of Biological Chemistry</i> , 2009, 284, 414-425.	3.4	30
27	Uridine-Based Inhibitors as New Leads for Antibiotics Targeting <i>Escherichia coli</i> LpxC. <i>Biochemistry</i> , 2009, 48, 3068-3077.	2.5	46
28	Discovery of new biosynthetic pathways: the lipid A story. <i>Journal of Lipid Research</i> , 2009, 50, S103-S108.	4.2	178
29	Purification and Mutagenesis of LpxL, the Lauroyltransferase of <i>Escherichia coli</i> Lipid A Biosynthesis. <i>Biochemistry</i> , 2008, 47, 8623-8637.	2.5	42
30	A New Link in the Biosynthesis and Transport of Lipid A - Interaction of MsbA and LpxK. <i>FASEB Journal</i> , 2008, 22, 815.2.	0.5	0
31	Structure-Activity Relationship of 2-Oxoamide Inhibition of Group IVA Cytosolic Phospholipase A ₂ and Group V Secreted Phospholipase A ₂ . <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4222-4235.	6.4	66
32	Differential Inhibition of Group IVA and Group VIA Phospholipases A ₂ by 2-Oxoamides. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2821-2828.	6.4	41
33	Synthesis and activity of 2-oxoamides containing long chain $\hat{2}$ -amino acids. <i>Journal of Peptide Science</i> , 2005, 11, 431-435.	1.4	22
34	Inhibition of Group IVA Cytosolic Phospholipase A ₂ by Novel 2-Oxoamides in Vitro, in Cells, and in Vivo. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 3615-3628.	6.4	92
35	In Vivo Phospholipase Activity of the <i>Pseudomonas aeruginosa</i> Cytotoxin ExoU and Protection of Mammalian Cells with Phospholipase A ₂ Inhibitors. <i>Journal of Biological Chemistry</i> , 2003, 278, 41326-41332.	3.4	172
36	Essential Ca ²⁺ -independent Role of the Group IVA Cytosolic Phospholipase A ₂ C2 Domain for Interfacial Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 23842-23850.	3.4	69

#	ARTICLE	IF	CITATIONS
37	Novel 2-Oxoamide Inhibitors of Human Group IVA Phospholipase A2. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 2891-2893.	6.4	72
38	The expanding superfamily of phospholipase A2 enzymes: classification and characterization. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2000, 1488, 1-19.	2.4	1,171
39	Group IV Cytosolic Phospholipase A2 Binds with High Affinity and Specificity to Phosphatidylinositol 4,5-Bisphosphate Resulting in Dramatic Increases in Activity. <i>Journal of Biological Chemistry</i> , 1998, 273, 2184-2191.	3.4	166